Abstract
Introduction: The introduction of elexacftor/tezacaftor/ ivacaftor (ETI) therapy has resulted in a paradigm shift in nutritional management of cystic fibrosis (CF). ETI is associated with increased weight, improved nutritional status and reduced pulmonary exacerbations. As a result, the number of individuals requiring tube feeding has fallen and gastrostomy tubes (G-tubes) are being proactively removed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
